Compare Biogen Inc (BIIB) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Salesforce Inc — how do they compare? Biogen Inc trades at $208.69 (market cap $30.13B), while Salesforce Inc trades at $192.66 (market cap $161.73B). The key difference: Salesforce Inc is far larger — about 5.4× Biogen Inc's market cap, and Salesforce Inc pays a 0.89% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | CRM | |
|---|---|---|
Market Cap | $30.13B | $161.73B |
Sector | Health | Technology |
52-Week High | $216.63 | $266.23 |
52-Week Low | $128.93 | $150.12 |
Enterprise Value | $37.20B | $191.77B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Salesforce (CRM) trades at $192.33, down 2.62% amid broader software sector weakness driven by AI disruption concerns. The stock maintains strong fundamentals with consistent earnings beats, 77.64% gross margins, and 18.73% net income margin. Technical indicators show bullish momentum despite overbought RSI readings, with key support at $193. Analyst consensus remains strongly bullish with a $230.83 price target representing 20% upside potential.
CRM presents a compelling investment case with robust profitability, AI monetization growth, and discounted valuation. Near-term risks include software sector volatility and AI competition, but strong cash flow generation and institutional support provide stability. The current dip offers entry opportunity for long-term investors seeking exposure to enterprise software leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
